Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	1	Date of announcement	2023/05/26	Time of announcement	19:38:52
Subject	The company's Board of Directors has resolved to replace the accounting firm and the certified public accountants				
Date of events	2023/05/26	To which item it meets	Paragraph 7		
Statement	 Incess Date of the board of directors submitted or approved: 2023/05/26 Name of the original accounting firm: PricewaterhouseCoopers, Taiwan Name of the original CPA 1: Juanlu, Man-Yu Name of the original CPA 2: Lin, Ya-Hui Name of the new accounting firm: Ernst & Young, Taiwan Name of the new CPA 1: Kuo, Shao-Pin Name of the new CPA 2: Yu Muriel Reason for the replacement: Due to the company's long-term strategic development and overall management needs. Specify whether the company or the original CPA decided to terminate or discontinue the appointment: The company discontinued the appointment. The date the company notified or was notified by the CPA about the termination: 2023/05/26 Were there adjustments to or suggestions on major internal control improvement matters in financial report that have been filed or are being prepared in the last 2 fiscal years: none Was there any divergence in opinion between the Company and the original CPA concerning above adjustments or suggestions? (If so, please specify.): NA Whether the original CPA is authorized to respond to the reasonable inquiries (including diverging opinions on above matters) from the new CPA: Yes Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 7 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The financial report will be certified by the new accounting firm from the second quarter of 2023. 				